Galderma's Nemolizumab Shows Sustained Efficacy in Young Atopic Dermatitis Patients
Event summary
- Galderma presented late-breaking phase II data at AAD 2026 showing nemolizumab effectively reduced skin lesions and itch in children aged 2-11 with moderate-to-severe atopic dermatitis.
- 41-47% of patients achieved clear or almost clear skin by Week 16, with sustained benefits up to Week 52.
- The treatment demonstrated a similar safety profile to its use in adults and adolescents.
- Nemolizumab is already approved for adults/adolescents with atopic dermatitis and adults with prurigo nodularis.
The big picture
Galderma's positive phase II data for nemolizumab in young children represents a strategic advance in addressing a critical gap in pediatric dermatology. The sustained efficacy and safety profile could position the drug as a leading option if regulatory approvals follow, while reinforcing Galderma's focus on therapeutic dermatology. This moves comes amid growing competition in the atopic dermatitis space, where pediatric indications remain particularly underserved.
What we're watching
- Regulatory Pathway
- Whether Galderma can leverage these pediatric data to expand nemolizumab's approval to younger patients, potentially unlocking a significant new market segment.
- Competitive Positioning
- How this differentiates nemolizumab from existing treatments in the crowded atopic dermatitis space, particularly for pediatric use.
- Commercial Strategy
- The pace at which Galderma can translate these results into market share gains, especially given the high unmet need in this patient population.